Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Carcinoma, Transitional Cell × naptumomab estafenatox × 1 year × Clear all

Sponsor

Conditions

Urinary Bladder Neoplasms 1 Triple Negative Breast Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Prostatic Neoplasms 1 Ovarian Neoplasms 1 Mesothelioma 1 Melanoma 1 Esophageal Squamous Cell Carcinoma 1 Esophageal Neoplasms 1 Endometrial Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Hepatocellular 1 Adenocarcinoma Of Esophagus 1

Interventions

pembrolizumab 38 Gemcitabine 20 enfortumab vedotin 19 Cisplatin 17 Nivolumab 16 atezolizumab 14 Magnetic Resonance Spectroscopy 14 avelumab 13 Carboplatin 12 Specimen Handling 10 Docetaxel 10 sacituzumab govitecan 9 Paclitaxel 7 Ipilimumab 7 Fluorodeoxyglucose F18 5 pemigatinib 4 toripalimab 3 erdafitinib 3 durvalumab 3 cabozantinib 3 X-Rays 3 Taxes 3 Mitomycin 3 Immunoglobulin G 3 CTLA-4 Antigen 3 Biopsy 3 tislelizumab 2 lenvatinib 2 eribulin 2 dodecyl maltoside 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡